Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870033 | 0.88 | GRM5 (0.48) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL8214117 | 0.88 | GRM5 (0.46) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1011447 | 0.86 | GRM5 (0.53) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1008923 | 0.86 | GRM5 (0.53) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1010399 | 0.86 | GRM5 (0.53) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL3817473 | 0.84 | GRM5 (0.41) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1863985 | 0.82 | ESR2 (0.51) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1010706 | 0.80 | ALDH1A1 (0.52) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL1868540 | 0.79 | GRM5 (0.64) | GRM5ALDH1A1TDP1GAAMAPT | |
| SCHEMBL8214680 | 0.79 | GRM5 (0.64) | GRM5ALDH1A1TDP1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | claimed |
| EP-2054421-B1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-11-17 | — | — | EP | claimed |
| EP-2054421-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | claimed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2008015270-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | claimed |
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | disclosed |
| EP-2054421-B1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2054421-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015270-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM3, GRM1 | GRM5 1/4885ALDH1A1 4053/4885TDP1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.